- Home
- LODE vs CGTX Comparison
LODE vs CGTX Comparison
Compare LODE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LODE | CGTX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LODE | CGTX |
|---|---|---|
| Price | $3.27 | $1.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $4.00 | $2.88 |
| AVG Volume (30 Days) | 831.1K | ★ 942.9K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,778,445.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,798.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.99 | N/A |
| 52 Week Low | $1.67 | $0.22 |
| 52 Week High | $10.10 | $3.83 |
Technical Indicators
Market Signals| Indicator | LODE | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 50.14 |
| Support Level | $3.13 | $1.69 |
| Resistance Level | $3.75 | $1.76 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 25.00 | 55.56 |
Price Performance
Historical ComparisonAbout LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.